Literature DB >> 24607411

Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection.

Soo Jung Kim1, Jinwoo Lee2, Young-Jae Cho3, Young Sik Park2, Chang-Hoon Lee2, Ho Il Yoon3, Sang-Min Lee2, Jae-Joon Yim2, Jae Ho Lee3, Chul-Gyu Yoo2, Choon-Taek Lee3, Young Whan Kim2, Sung Koo Han2, Hong Bin Kim4, Jong Sun Park5.   

Abstract

OBJECTIVES: The incidence of Pneumocystis jirovecii pneumonia (PCP) in patients without HIV infection (non-HIV PCP) has been increasing along with the increased use of chemotherapeutic agents and immunosuppressants, but the prognostic factors of non-HIV PCP remain unclear. This study aimed to identify the prognostic factors of non-HIV PCP.
METHODS: Immunocompromised patients without HIV infection who were diagnosed and treated for PCP were included. The PCP diagnosis was based on positive direct fluorescent antibody (DFA) or polymerase chain reaction (PCR) results and compatible clinical symptoms and radiological findings.
RESULTS: In total, 372 non-HIV patients with positive PCP DFA or PCR findings were screened and 173 were included. Univariate analysis indicated that age, smoking, chronic lung disease or hematologic malignancy, chemotherapeutic agents, high alveolar-arterial oxygen gradient (D[A-a]O2), C-reactive protein, albumin, blood urea nitrogen (BUN), CMV antigenemia, combined bacteremia, high percentage of neutrophils and rate of co-infection in BAL fluid, and mechanical ventilator care were related to the prognosis of non-HIV PCP. Multivariate analysis revealed that high D(A-a)O2, combined bacteremia, increased BUN and preexisting lung disease were indicators of a poor prognosis.
CONCLUSIONS: High D(A-a)O2, combined bacteremia, increased BUN and preexisting lung disease were independent factors of poor prognosis in non-HIV PCP patients.
Copyright © 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immunocompromised patients; Pneumocystis jirovecii pneumonia; Prognostic factor

Mesh:

Year:  2014        PMID: 24607411     DOI: 10.1016/j.jinf.2014.02.015

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  21 in total

1.  Combine use of glucocorticoid with other immunosuppressants is a risk factor for Pneumocystis jirovecii pneumonia in autoimmune inflammatory disease patients: a meta-analysis.

Authors:  Huyu Wang; Lili Shui; Yajuan Chen
Journal:  Clin Rheumatol       Date:  2022-09-23       Impact factor: 3.650

2.  Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.

Authors:  Anlei Liu; Ruixue Sun; Guanghui Cao; Xiaohang Liu; Huadong Zhu; Jing Yang
Journal:  BMC Infect Dis       Date:  2022-06-14       Impact factor: 3.667

3.  Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death.

Authors:  Minjiang Chen; Xinlun Tian; Fang Qin; Jiong Zhou; Jinjing Liu; Mengzhao Wang; Kai-Feng Xu
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

4.  Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis.

Authors:  Yao Liu; Lili Su; Shu-Juan Jiang; Hui Qu
Journal:  Oncotarget       Date:  2017-08-04

5.  Risk Factors of Mortality From Pneumocystis Pneumonia in Non-HIV Patients: A Meta-Analysis.

Authors:  Yuqiong Wang; Xiaoyi Zhou; Maidinuer Saimi; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan
Journal:  Front Public Health       Date:  2021-06-16

6.  Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.

Authors:  Stine Grønseth; Tormod Rogne; Raisa Hannula; Bjørn Olav Åsvold; Jan Egil Afset; Jan Kristian Damås
Journal:  BMC Infect Dis       Date:  2021-07-07       Impact factor: 3.090

Review 7.  Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review.

Authors:  Magdalena Sokulska; Marta Kicia; Maria Wesołowska; Andrzej B Hendrich
Journal:  Parasitol Res       Date:  2015-08-19       Impact factor: 2.289

8.  Multiple nodular lesions following Pneumocystis pneumonia in a non-HIV immunocompromised patient.

Authors:  Takanori Asakura; Naofumi Kameyama; Makoto Ishii; Ichiro Kawada; Sadatomo Tasaka; Kenzo Soejima; Tomoko Betsuyaku
Journal:  Clin Case Rep       Date:  2016-04-01

Review 9.  Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak.

Authors:  Norihiko Goto; Kenta Futamura; Manabu Okada; Takayuki Yamamoto; Makoto Tsujita; Takahisa Hiramitsu; Shunji Narumi; Yoshihiko Watarai
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-11-15

10.  Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study.

Authors:  Li Weng; Xu Huang; Lie Chen; Li-Qin Feng; Wei Jiang; Xiao-Yun Hu; Jin-Min Peng; Chun-Yao Wang; Qing-Yuan Zhan; Bin Du
Journal:  BMC Infect Dis       Date:  2016-09-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.